InvestorsHub Logo
Followers 617
Posts 27445
Boards Moderated 3
Alias Born 11/16/2007

Re: maz100577 post# 83673

Monday, 12/22/2014 11:35:08 AM

Monday, December 22, 2014 11:35:08 AM

Post# of 402726
I'm thinking the FDA was given some concrete results to look at this month or they wouldn't have given Brilacidin for ABSSSI the QIDP designation.
http://cellceutix.com/cellceutix-antibiotic-brilacidin-receives-qidp-designation-from-fda/#sthash.Y1xKjDbV.dpbs

Plus, the FDA also gave the go ahead on a phase II for Prurisol this month:
http://cellceutix.com/cellceutix-prurisol-for-psoriasis-fda-agrees-that-phase-2-study-may-begin/#sthash.uRrUhooP.dpbs

So, I don't believe we lack concrete results.

Edit to add: Follow this link and as time progresses you will see more concrete results:
https://clinicaltrials.gov/ct2/results?term=cellceutix





In Reply to 'maz100577'
The problem is CTIX is not "beyond" releases like the one from this a.m. CTIX IS releases like the one from this a.m. That's who they are, that's what they do. There has never been a PR, ever, with statistical results from a human clinical trial. The sp escalation may make it appear like the company is "beyond" releases like this but releases like this are what drove the share price escalation....sp appreciation doesn't change or legitimize the business operation. The lack of concrete results will be the eventual undoing...it's simply a matter of time...





To follow KarinCA, click here then click "Follow This Member" under my photo.

Be kinder than necessary, for everyone you meet is fighting some kind of battle.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News